Clinical Outcomes for Impella Patients Associated with Hyperlipidemia: An Analysis of the National Inpatient Sample

The Impella, a ventricular assist device, is crucial for managing severe heart failure and cardiogenic shock. Despite its widespread use, there's scant information on how hyperlipidemia affects Impella patients. To address this gap, we delved into the National Inpatient Sample Database from 2019 and 2020. Our aim was to scrutinize in-hospital outcomes among these patients. We identified 8233 Impella patients, among whom 1012 (12.3%) had hyperlipidemia. Those with hyperlipidemia displayed higher rates of hypertension, diabetes mellitus, and chronic kidney disease compared to their counterparts without hyperlipidemia. Shockingly, in-hospital mortality was notably elevated in the hyperlipidemia group, emphasizing its clinical significance. After meticulous multivariate regression analysis, it became evident that hyperlipidemia was a significant risk factor for heightened inpatient mortality and escalated total hospital charges. Additionally, these patients endured prolonged hospital stays. Further analysis unveiled that hyperlipidemia amplified the odds of complications such as acute kidney failure, ventricular arrhythmia, stroke, deep vein thrombosis, and sepsis. In summary, our nationally representative retrospective cohort study underscores the detrimental impact of hyperlipidemia on Impella patients. These findings advocate for tailored management strategies and heightened vigilance in this high-risk subgroup to ameliorate outcomes and enhance patient care.